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Abstract: Toxicogenomics, based on the temporal effects of drugs on gene expression, is 
able to predict toxic effects earlier than traditional technologies by analyzing changes in 
genomic  biomarkers  that  could  precede  subsequent  protein  translation  and  initiation  of 
histological  organ  damage.  In  the  present  study  our  objective  was  to  extend  in  vivo 
toxicogenomic screening from analyzing one or a few tissues to multiple organs, including 
heart,  kidney,  brain,  liver  and  spleen.  Nanocapillary  quantitative  real-time  PCR  
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(QRT-PCR)  was  used  in  the  study,  due  to  its  higher  throughput,  sensitivity  and 
reproducibility,  and  larger  dynamic  range  compared  to  DNA  microarray  technologies. 
Based on previous data, 56 gene markers were selected coding for proteins with different 
functions,  such  as  proteins  for  acute  phase  response,  inflammation,  oxidative  stress, 
metabolic  processes,  heat-shock  response,  cell  cycle/apoptosis  regulation  and  enzymes 
which are  involved  in detoxification. Some of the  marker genes are specific to certain 
organs, and some of them are general indicators of toxicity in multiple organs. Utility of 
the nanocapillary QRT-PCR platform was demonstrated by screening different references, 
as well as discovery of drug-like compounds for their gene expression profiles in different 
organs of treated mice in an acute experiment. For each compound, 896 QRT-PCR were 
done: four organs were used from each of the treated four animals to monitor the relative 
expression of 56 genes. Based on expression data of the discovery gene set of toxicology 
biomarkers the cardio- and nephrotoxicity of doxorubicin and sulfasalazin, the hepato- and 
nephrotoxicity  of  rotenone,  dihydrocoumarin  and  aniline,  and  the  liver  toxicity  of  
2,4-diaminotoluene could be confirmed. The acute heart and kidney toxicity of the active 
metabolite SN-38 from its less toxic prodrug, irinotecan could be differentiated, and two 
novel gene markers for hormone replacement therapy were identified, namely fabp4 and 
pparg, which were down-regulated by estradiol treatment. 
Keywords: toxicogenomics; organ toxicity; real-time PCR; gene expression 
Abbreviations: QRT-PCR: quantitative real-time PCR; ADME: absorption, distribution, 
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1. Introduction 
Gene expression profiling of drug or xenobiotic exposed cells or animals is rapidly becoming a 
standard analysis in toxicology, and has the potential to play a pivotal role in all stages of drug safety 
evaluation including preclinical and clinical studies. Toxicogenomics is an emerging technology that 
uses  novel  genomic  technologies  to  investigate  the  adverse  effects  of  small  molecules  at  the 
transcriptome  level [1–3]. Among the applied technologies, DNA  microarrays and new generation 
sequencing methods have the capability to screen drug-induced gene expression changes at a global 
scale [4,5]. 
These up-to-date technologies are allowing researchers to gain an increased understanding of the 
function and regulation of genes and to identify pathways that are affected. 
Toxicogenomics is based on the fact that most relevant toxicological effects of a compound affect 
directly or indirectly the gene expression. In order to demonstrate that different mechanisms of toxicity 
can be determined from gene expression data, Dai et al. have analyzed expression profiles of samples 
from rodents treated with 49 known hepatotoxins and 10 compounds without known liver damage. By 
using  their  bioinformatic  tools  compound-induced  liver  toxicity  could  be  predicted  with  90.9% 
sensitivity and 88.4% specificity [6]. In another study Hamadeh et al. tested the hypothesis that cDNA Int. J. Mol. Sci. 2011, 12  6118 
 
 
microarrays are an applicable platform for chemical-specific gene-expression profiling [7]. Relative 
expression  changes  were  clustered  and  correlated  to  histopathology  and  chemical  data,  which 
corresponded well. Thus, it may be possible to determine if the compound has potential toxicity by 
comparing the gene expression profiles of an unknown compound against a reference database. 
The  most  important  advantage of toxicogenomics  is  the  early  predictive  capability  based on the 
temporal  effects  of  drugs  on  gene  expression:  changes  in  genomic  biomarkers  may  occur  before 
subsequent protein translation and initiation of histological organ damage. Most of the previous studies 
focused on only one tissue or organ, such as liver [8–11], kidney [12], spleen [13], lung [14], brain [15], 
or one type of toxic insult, such as genotoxicity and carcinogenecity [16] or phospholipidosis [17]. 
In the present study our objective was to extend in vivo toxicogenomic screening from analyzing 
one or a few tissues to multiple organs. Because of the biological variation of the tested animals in  
our standard protocol eight animals were used (4 treated and 4 buffer-treated controls). From each 
animal,  four  different  organs  (liver,  kidney,  heart  and  brain)  were  collected  to  study  their  gene 
expression profiles. 
Although  DNA  microarray  technology  became  a  powerful  screening  tool  for  gene  expression 
profiling  in  toxicogenomics,  not  only  sensitivity  and  dynamic  range  are  small,  but  in  our  set-up 
screening of each drug candidate would need 32 microarrays. Therefore, when multiple samples are 
intended to be analyzed for organ-specific toxicity, application of DNA microarrays are technically 
challenging and expensive. 
Moreover, standardization of data analysis and comparison can be difficult because of different 
platforms  available.  Quantitative  real-time  PCR  (QRT-PCR) remains  one  of  the  gold  standards  in 
accurate determination of gene expression changes and has been already applied to validate microarray 
data in toxicogenomic studies and for molecular phenotyping [18–21]. 
The high sensitivity, reproducibility, and large dynamic range of traditional QRT-PCR provides 
high-throughput  and  accurate  differential  expression  profiling  of  usually  10–20  selected  genes. 
However,  one  of  the  drawbacks  of  application  of  traditional  QRT-PCR  in  toxicogenomics  is  the 
relatively low throughput and the small number of genes that can be analyzed on multiple samples. 
Recently, a novel, nanocapillary-based QRT-PCR has been established with a capacity of running 
approximately 18,000 reactions per day in one OpenArray
TM Cycler (Biotrove, Applied Biosystems). 
The system runs with high accuracy, precision and provides dynamic range characteristic of QRT-PCR 
with the relatively higher throughput of microarrays: 3072 individual solution-phase reactions are run 
parallel in 33 nL through-holes on the size of a microscope slide in a thermal cycler. This platform is 
optimal  for  analyzing  numerous  samples  over  56–112  gene  markers.  Previously  the  analytical 
performance  of  this  technology  and  its  general  applicability  for  the  field  of  toxicogenomics  was 
confirmed by screening 668 compounds for their gene expression profiles in vitro in HepG2 cells [2]. 
In this study we have also demonstrated that a focused set of marker genes can be used for finding the 
correlation between a library of molecular scaffolds and their general biological fingerprint. 
In the present study, reference as well as discovery drug-like compounds were screened for their 
gene expression profiles in different organs of treated mice over a discovery gene set of 56 toxicology 
biomarkers. Marker genes were selected from DNA-microarray and literature data that cover different 
pathways  altered  during  toxic  insults  in  the  brain,  lungs,  spleen,  heart,  liver  and  kidney.  We 
demonstrated that using high-throughput QRT-PCR technology for in vivo toxicogenomic study of Int. J. Mol. Sci. 2011, 12  6119 
 
 
different organs from treated animals can be used for preclinical studies and could accurately predict 
organ-specific toxic side effects. 
2. Results and Discussion  
2.1. Results 
2.1.1. Development of a Toxicogenomic Nanocapillary QRT-PCR Platform 
Although DNA-microarray technology is able to determine the expression of virtually all genes in 
the  genome,  application  of  this  approach  in  a  medium-throughput  screening  project  is  labor  and 
material intensive and it generates overwhelming data with no predictive value on toxic side effects. 
Therefore it is feasible to identify a smaller number of genes that may serve as selective markers for 
early toxicogenomic screening. Previously we demonstrated the utility of high-throughput, nanocapillary 
QRT-PCR  system,  which  uses  the  OpenArray
TM  Cycler  from  Applied  Biosystems  (previously 
BioTrove) [2]. It joins high accuracy, precision and dynamic range characteristic of QRT-PCR with 
the higher throughput of microarrays: 3072 individual solution-phase reactions are running in parallel 
in a matrix of 48 submatrices having 64 through-holes in each (out of which 56 can be used for gene 
expression profiling). Low sample-volumes (33 nL in each hole), high number of reaction chambers; 
the 48 individually addressable submatrices and the software-controlled data processing and analysis 
make the system ideal for toxicogenomic screening. Because of the characteristics of the nanocapillary 
system definition of 56 genes (or 2 × 56 genes) are optimal for large scale toxicogenomic analysis. By 
selecting 56 genes one can analyze up-to 144 samples per run. Because of the high sample number we 
designed our toxicogenomic platform to be able to determine organ-specific toxicity. Accordingly, we 
selected  56  genes  from  DNA-microarray  and  literature  data  that  cover  different  pathways  altered 
during toxic insults in different organs: the brain, lungs, spleen, heart, liver and kidney. The list of the 
selected genes, the organs that have been correlated with their toxic effects and the references are 
shown in Table 1. The selected genes can be classified by their functions: they code for proteins for 
acute phase response (saa3, anxa2, fga, ftl1), inflammation (tubb5, reg3a, serpine1, fabp4, serpinci, 
fas),  oxidative  stress  (gadd153,  nox3,  ldh3b,  prdx3,  alox12b,  akr1b8,  prdx1,  sod1,  nqo1,  cfos), 
metabolic  processes  (oazi,  timp3,  pepck,  hsd3b4,  odc1,  kap,  rbp4,  aadat,  pgam2,  ndufa5,  ptpmt1, 
timp2,  klk1b3),  heat-shock  response  (dnaja2,  hspcb,  hspa1a),  cell  cycle/apoptosis  regulation  (clu, 
spp1, vim, ccng1, egf, psmb8, ubc, pcna) and enzymes which are involved in detoxification (gstp2, oat, 
hsd17b4, cyp1a1, cyp7a1, ephx1, slc25a6). Three housekeeping genes were selected (ppia, pgk1 and 
rplp0) and their average expression was used for normalization. Int. J. Mol. Sci. 2011, 12  6120 
 
 
Table 1. List of marker genes, their references and Taqman probes used in this study. 
#  Gene  Name  Accession No.  Probe Name  Organ  Ref. 
1  GADD153  DNA-damage-inducible 3  NM_007837.3  Mm00492097_m1  liver  [7,21] 
2  SAA3  serum amyloid A 3  NM_011315.3  Mm00441203_m1  liver, lung  [22] 
3  TIMP3  metallopeptidase inhibitor 3  NM_011595.2  Mm00441827_m1  liver, lung  [22] 
4  PEPCK 
phosphoenolpyr. 
carboxykinase  NM_011044.2  Mm00440636_m1  liver  [5] 
5  NOX3  NADPH oxidase 3  NM_198958.2  Mm01339132_m1  kidney  [6] 
6  Hsd3b4  hydroxy-d-5-steroid dehyd.  NM_001111336  Mm00843753_s1  liver  [7] 
7  Clu  clusterin  NM_013492.2  Mm00442773_m1  kidney, liver  [7,11] 
8  Spp1  secreted phosphoprotein 1  NM_001204201  Mm00436767_m1  kidney  [11] 
9  vim  vimentin  NM_011701  Mm01333430_m1  kidney  [11] 
10  Anxa2  annexin A2  NM_007585.3  Mm00500307_m1  kidney  [23] 
11  Tubb5  tubulin, beta 5  NM_011655.5  Mm00495804_m1  kidney  [11] 
12  Gstp2  glutathione S-transferase, pi 2 NM_181796.2  Mm00839138_g1  kidney  [7] 
13  Fga  fibrinogen alpha chain  NM_001111048  Mm00802584_m1  kidney  [24] 
14  Ccng1  cyclin G1  NM_009831.2  Mm00438084_m1  kidney  [11] 
15  Klk1b3 
kallikrein 1-related peptidase 
b3  NM_008693.2  Mm01203825_gH  kidney  [11] 
16  Odc1  ornithine decarboxylase 1  NM_013614.2  Mm01964631_g1  kidney  [11] 
17  Kap 
kidney androgen regulated 
prot.  NM_010594.2  Mm00495104_m1  kidney  [11] 
18  Oat  ornithine aminotransferase  NM_016978.2  Mm00497544_m1  kidney  [11] 
19  Rbp4  retinol binding protein 4  NM_001159487  Mm00803266_m1  kidney  [11] 
20  Aadat 
aminoadipate 
aminotransferase  NM_011834.2  Mm00496169_m1  kidney  [11] 
21  Egf  epidermal growth factor  NM_010113.3  Mm01316968_m1  kidney  [11] 
22  Pgam2  phosphoglycerate mutase 2  NM_018870.3  Mm00450782_g1  heart  [25] 
23  Hsd17b4 
hydroxysteroid 
dehydrogenase 4  NM_008292.4  Mm00500443_m1  heart  [25] 
24  Idh3B 
isocitrate dehydrogenase 3 
beta  NM_130884.4  Mm00504589_m1  heart  [25] 
25  Ndufa5 
NADH dehydrogenase 1 
alpha 5  NM_026614.2  Mm00471676_g1  heart  [25] 
26  Prdx3  peroxiredoxin 3  NM_007452.2  Mm00545848_m1  heart  [25] 
27  Alox12b  arachidonate 12-lipoxygenase NM_009659.2  Mm00507782_m1  heart, brain  [26] 
28  Reg3a  regenerating islet-derived 3a NM_011259.1  Mm00441121_m1  heart, liver  [27] 
29  Cyp1a1  cytochrome P450, family 1a1 NM_001136059  Mm00487218_m1  liver  [7] 
30  SERPINE1  serine peptidase inhibitor E1 NM_008871.2  Mm00435860_m1  heart, kidney  [28] 
31  CYP7A1  cytochrome P450, family 7a1 NM_007824.2  Mm00484152_m1  heart, liver  [29] 
32  Akr1b8 
aldo-keto reductase family 
1B8  NM_008012.1  Mm00484314_m1  spleen  [12] 
33  FABP4  fatty acid binding protein 4  NM_024406.2  Mm00445878_m1  spleen  [12] Int. J. Mol. Sci. 2011, 12  6121 
 
 
Table 1. Cont. 
34  Ptpmt1  protein tyrosine phosphatase 1  NM_025576.2  Mm00458631_m1  spleen  [30] 
35  HINT1 
histidine triad nucl. binding 
prot.  NM_008248.2  Mm00801722_m1  spleen  [30] 
36  PSMB8  proteasome subunit, beta 8  NM_010724.2  Mm00440207_m1  spleen  [30] 
37  Hoxa2  homeobox A2  NM_010451.1  Mm00439361_m1  brain  [22] 
38  DNAJA2  DnaJ (Hsp40) homolog,A2  NM_019794.4  Mm00444898_m1  lung, liver  [7,13] 
39  OAZI  antizyme inhibitor 1  NM_001102458  Mm00497630_m1  lung  [13] 
40  SLC25A6  solute carrier family 25A6  NM_026255.5  Mm00470958_m1  lung  [13] 
41  SERPINCI serpin peptidase inhibitor, C1 NM_000488.3  Mm00446573_m1  lung  [13] 
42  HSPCB 
heat shock protein 90 alpha 
B1  NM_008302.3  Mm00833431_g1  lung  [13] 
43  UBC  ubiquitin C  NM_019639.4  Mm01201237_m1  lung  [13] 
44  TIMP2  tissue inhib. metalloprot. 2  NM_011594.3  Mm00441825_m1  lung  [13] 
45  FAS 
Fas (TNF receptor 
superfamily 6)  NM_001146708  Mm01204974_m1  liver  [31,32] 
46  PCNA 
proliferating cell nuclear 
antigen  NM_011045.2  Mm00448100_g1  liver  [7,11] 
47  PRDX1  peroxiredoxin 1  NM_011034.4  Mm01621996_s1  liver, lung  [7] 
48  Ephx1  epoxide hydrolase 1  NM_010145.2  Mm00468752_m1  spleen  [7] 
49  Hspa1a  heat shock protein 1A  NM_010479.2  Mm01159846_s1  liver  [7] 
50  SOD1  superoxide dismutase 1  NM_011434.1  Mm01344233_g1  liver, heart  [7] 
51  Ftl1  ferritin light chain 1  NM_010240.2  Mm03030144_g1  liver, spleen  [12] 
52  Nqo1  NAD(P)H dehydrogenase 1  NM_008706.5  Mm00500821_m1  liver  [7] 
53  c-Fos  FBJ osteosarcoma oncogene NM_010234.2  Mm00487425_m1  liver  [7,21] 
54  PPIA  peptidylprolyl isomerase A  NM_008907.1  Mm02342430_g1  control  - 
55  PGK1  phosphoglycerate kinase 1  NM_000291.3  Mm00435617_m1  control  - 
56  RPLP0  ribosomal protein, large, P0  NM_007475.5  Mm00725448_s1  control  - 
Because  of  the  relatively  high  number  of  animals  needed  for  our  toxicogenomic  platform  we 
designed  our  gene  sets  for  mouse;  however  the  same  set  of  genes  could  be  designed  for  other 
organisms as well, such as for rat or rabbit. The discovery set of gene markers presented here can be 
also further optimized and could be revised in each order of the OpenArray
TM plates. 
2.1.2. In Vivo Protocol for Toxicogenomic Profiling of Multiple Organs 
In the present study our objective was to extend in vivo toxicogenomic screening from analyzing 
one or a few tissues to multiple organs. Because of individual differences of the tested animals, four 
animals  are  used  in  each  group  treated  either  with  control  solubilization  buffer  or  with  a  toxic 
reference or a drug-like compound. In the present study four different organs (liver, kidney, heart and 
brain) were isolated from each animal to study their gene expression profiles. However, other organs, 
such as lungs, spleen, testis, ovary can be also analyzed with our technology, as several gene markers 
overlap between different organs. Marker gene design was also based on previous studies on different 
cells and tissues (Table 1), moreover other new markers could also be inserted into our list, therefore 
adaptation of the high-throughput QRT-PCR for analyzing virtually any tissues can easily be done. Int. J. Mol. Sci. 2011, 12  6122 
 
 
Based on the expression data from six hepatotoxins in rat livers obtained on DNA microarray at 
multiple time-points, Bulera et al. found that the expression profiles from the same compounds clustered 
together regardless of treatment duration [33]. This indicates that individual compounds give unique 
expression signatures and the treatment duration can be standardized in a toxicogenomic study. Different 
tested compounds were applied for 16 h and brains, hearts, kidneys and livers were isolated afterwards. 
Because of the different solubility of the tested compounds a solubilization procedure was used, which 
successfully increased the solubility of different compounds. The compounds were dissolved in DMSO, 
then a non-ionic detergent, Solutol (BASF, Germany) was added and finally saline was used to obtain a 
clear solution, which could be injected intraperitoneally. This administration route was used to determine 
systemic effects and to avoid differences in bioavailibility of the different drugs. After organ isolation, 
RNA was stabilized in RNA-Later (Ambion, Life Technologies, USA) at 4 °C for 16 h. After RNA 
purification and cDNA conversion the templates were applied to each sub-matrix of the OpenArray
TM 
plate. In one run four different organs from animals of three different treatments and one control group 
could be analyzed in quadruplicates (biological replicates). 
The  schematic  representation  of  the  present  protocol  can  be  seen  in  Figure  1.  Although  one 
concentration from each tested compound was used based on known LD50 data, one can analyze different 
concentrations of the same drug to determine safe dosing of the drug candidate by simply analyzing the 
gene expression profiles.  
Figure 1. Schematic representation of our organ-specific toxicogenomic screening based 
on nanocapillary QRT-PCR technology. 
 
2.1.3. Profiling of Known Toxic Reference Compounds 
To test our toxicogenomic profiling approach, we determined how known toxic reference compounds 
affect the expression of the selected marker genes and whether we can record organ-specific alterations 
based on the expression profiles. At first in a verification study doxorubicin, sulfasalazin, rotenone, 
aniline, dihydrocoumarin and 2,4-diaminotoluene was injected into mice in the same carrier solution 
(20% DMSO, 25% Solutol, 55% saline) and compared the expression of genes to those obtained from 
animals  having  the  same  carrier  solution  with  no  compounds.  After  injecting  four  animals  with  
each compound intraperitoneally, four organs were collected: heart, brain, liver and kidney and they 
were  subjected to  mRNA  purification,  cDNA  conversion  and  nanocapillary  QRT-PCR.  After  data Int. J. Mol. Sci. 2011, 12  6123 
 
 
analysis different gene expression changes were found in response to different chemicals, moreover 
organ-specific changes for each toxic compound could be recorded (Figure 2). 
Figure  2.  Marker  gene  expression  profiles  of  different  reference  toxic  compounds. 
Differences are given in average ΔCt values after normalization to housekeeping genes. 
Green labels indicate repression, while red labels indicate induction of gene expression 
activity, compared to vehicle treated animals. For each treatment and for each organ we 
calculated the number of genes affected (induced or repressed) (see below in each column). 
GENE Brain Liver HeartKidney Brain Liver HeartKidney Brain Liver HeartKidney Brain Liver HeartKidney Brain Liver HeartKidney Brain Liver HeartKidney Brain Liver HeartKidney
Aadat -1.3 1.33 1.25 4.91 1 5.37 -1.2 -4.3 1.03 1.18 -1.6 1.78 1.49 -1.4 -1.9 2.6 1.18 1.8
Anxa2 1.8 4.72 3.1 3.3 1.99 1.01 1.69 4.94 -1.1 1.36 8.01 5.85 1.24 -1.3 -1.1 2.64 1.67 1.38 -1.5 3.22 -1.5 -1 1.3 -1.7 -1.3 1.1 1.13 1.1
Ccng1 1.24 2.37 23.2 3.09 1.76 3.11 3.23 10.6 -1.5 1.88 4.02 6.28 1.15 1.71 1.94 -1.1 1.25 1.52 -1.1 3.33 1.43 -1.2 -1.3 -1.3 -1 1.06
Clu 1.24 1.12 1.57 6.73 1.83 1.47 -1.1 5.14 1.43 1.41 3.61 3.01 2.34 1.51 -1.4 -1.3 1.36 1.11 -1.3 1.05 -1.4 1.43 1.16 -1.4 -1.6 1.38 1.12 1.17
DNAJA2 -1 2.27 16.2 2.37 1.68 2.2 2.53 4.07 -1.1 2.34 4.36 5.94 1.12 2.83 -1.1 3.07 1.05 2.26 -1 2.53 -25 1.35 -5 -8.2 1.42 -2.2
Egf 1.66 5.59 7.13 1.55 1.84 2.55 -1.7 1.84 1.04
Ephx1 1.02 -1.5 9.42 1.62 -1 1.63 2.05 3.24 -1.6 2.09 4.99 6.64 -1.1 1.99 -1.1 1.78 1.13 2.57 1.29 2.12 -1.7 1.53 -2.1 1.08 1.1 -1.6
FABP4 12 3.9 2.16 2.75 3.8 2.33 2.32 7.31 3.25 2.25 1.05 1.32 2.05 1.21 2.4 -1.9 1.13 1.16 -1.5 -1.1 -2.4 1.04 -1.4
Fga 13.7 56.7 3.2 3.76 2 4.99 3.38 8.59 1.56 -1.5 -1.5 -1.6 -1.1 1.48 -1.4 -1 -1.1 -1.7
Ftl1 2.54 1.18 10.1 4.16 1.49 1.74 1.82 5.63 -1 2.28 8.52 7.26 1.76 3.42 2.83 3.72 1.03 2.81 -1.1 4.48 -1.4 -1.3 -1.3 2.04
GADD153 1.41 4.41 3.07 6.51 1.81 1.67 2.12 5.55 1.17 2.26 4.76 5.23 2.17 9.15 1.3 1.44 3.05 -1.5 3.88 3.51 -1.1 -1 -2.5 1.57 2.75 1.55 -1.3
Gstp2 1.15 1.45 -1.5 -1.1 -1.4 1 -1.3 -1 -2.2 -1 -1.1 1.64 1.31 -1.1 1.4 1.4 1.04
HINT1 1.82 2.08 25.6 2.5 2.08 2.24 3.15 5.75 1.32 2.4 7.13 5.9 1.62 2.54 2 2.33 1.23 2.4 1.45 2.57 -1 1.49
Hsd17b4 1.86 -1.1 20.3 4.76 1.64 1.5 2.1 6.16 1.31 2.19 4.81 5.27 1.89 2.54 1.86 2.46 1.51 2.28 -1.3 1.92 -1.5 5.62 -1 -1.9 -1.3 4.06 -1 1.09
Hsd3b4 8.24 -1 2.57 3.25 1.81 3.35 1.63 -1.7 -1.3 -2.8 1.34 -1.1 1.25 1.09 1.15 1.19 1.04 -1.1
Hspa1a 3.24 1.65 1.52 -1.7 -1.4 2.01 1.07 -1.4 2.11 1.35 1.08 2.06 -1.6 1.29 1.68
HSPCB 1.18 1.03 10.2 3.39 1.81 2.56 -1.3 7.06 1.34 2.21 1.24 4.53 1.88 5.7 1.36 -1.3 1.3 4.21 -1.1 4.35 1.08 -3.2 -2 -1.8
Idh3B 1.44 1.32 16.1 2.77 1.43 1.68 2.85 5.81 -1.1 1.85 5.89 7.5 1.21 2.12 1.52 3.18 1.06 1.45 1.04 2.48 -1.8 1.38 1.09 -1.4 -1.6 1.38 1.58 1.1
Kap -1.3 1.1 1.77 -5 1.11 -1 -1.7 -2.1 1.26 -1.2 -1.1 -1
Nqo1 1.8 5.94 3.36 -1 3.66 3.33 -1.1 3.4 4.65 1.11 -1 1.54 1.19 1.15 1.23 1 -1.9 1.72 -1.4 -1.1 -1.8 1.09 -1.2
Oat 1.09 -1.1 12.2 1.07 -1.2 1.42 2.72 2.99 1.04 1.65 4.8 5.28 1.21 1.91 1.22 1.59 1.13 1.65 1.1 1.03 -3.6 -5.5 -1.4 -6.8 -1.8 -31 -1.1 -4.1
OAZI 1.77 1.15 4.14 1.93 -1.5 -1 4.88 4.69 1.09 1.23 5.61 1.19 1.03 1.27 -1.5 1.12 1.46 -1.3 -1.6 1.71 1.21 1.58 -1.1 1.6 1.07
Odc1 3.87 -1.9 5.22 -1.5 1.64 -1.9 -1 1.84 -1.1 -2.9 -1.1 4.68 -2.2 -1.9 -1.2 -5.3 -1.4 -2 -1.2 -1.3 -1.2 -1.1 -1.5 1.29 -1.2 1.83 1.17 1.05
PCNA 1.12 1.42 1.73 1.07 -1 1.3 1.43 -1.8 -1.4 4.38 3.34 -1.5 -1.6 -1.3 -1.1 -1.7 -2.4 1.46 1.1 1.65 -1.2 -1.6 -1 1.04 -1 -1.5
PEPCK 5.43 9.76 5.76 3.44 3.92 1.49 11 -3.2 3.07 2.69 -1.1 -2.7 -1.3 -2.3 -1 -1.6 -1.3 -1.8
Pgam2 1.1 3.2 1.18 1.35 1.29 2.19 -1.2 1.86 1.97 1.27 1.08 -27 1.31 -1.3 1.2 -1 -1.4 -1.9 2.25 1.92 1.78
PRDX1 3.78 -5.2 5.14 1.37 -1.1 -1.4 4.37 1.23 -1.4 -1.3 9.29 4.87 -2.4 -2.7 1.36 -1.7 -1.5 -1 1.71 2.39 5.06
Prdx3 1.09 2.24 10.9 -1.1 -1.3 1.68 2.39 2.39 -1.4 2.39 -1.6 1.56 1.05 2.22 1.7 1.16 1.91 1.27 1.23 -4 -4.1 -2.9 -1.8 -1.9 -2.6 -1.6 1.75
PSMB8 1.21 1.07 -1.1 -1.2 -1.6 -1.3 -1.1 -2.1 -1.3 1.21 -1.3 1.01
Ptpmt1 1.35 2.71 11.2 7.41 1.61 1.94 2.41 4.09 -1.4 1.93 6.19 6.01 -1.1 2.41 1.99 3.48 1.07 1.5 -1.5 2.11 -2.1 1.28 -1 -2 -1.5 1.27 1.09 1.06
Rbp4 -2 1.1 2.71 -1.1 2.01 1.76 -2.1 2.03 1.48 1.07 2.53 1.03 1.02 2.08 1.91 -1.8 1.18 1.13 -2.4 -1.5 1.67 1.26 1.13
SAA3 144 7.08 2.21 1.72 -1.7 1.07 1.49 1.31 1.25 -1.1 2.01 -1.1 -1.1
SERPINCI 1.14 1.95 2.09 1.77 1.8 -1.3 1.41
SERPINE1 10.4 1.12 -1 1.4 1.24 1.61 1.65 1.01 1.91 1.45 3.27
SLC25A6 2.75 1.57 3.45 2.9 1.29 1.88 2.59 2.36 3.4 1.91 1.1 3.67 2.15 -1.5 1.06 1.02 -1.3 -1.5 -1.9 1.1 1.05
SOD1 1.32 1.32 8.36 1.82 1.15 1.87 2.28 4.48 -1.3 2.2 4.48 6.41 -1.1 1.4 -1.4 1.63 1.06 1.51 -1.3 3.06 -2.8 -3.2 -2.3 -5.2 -1.6 -2 -1.4 -1.2
Spp1 9.15 2.92 28.4 2.22 3.5 5.9 1.05 1.6 5.76 1.18 -1.9 4.63 1.3 1.44 2.27 -1.9 1.39 1.18 -1.7 -1.8 1.22 1.02 1.05
TIMP2 1.18 -1.5 1.82 1.43 1.27 1.91 3.32 1.36 1.43 6.6 4.32 2.34 1.18 -1.1 1.46 1.22 1.47 1.07 1.59 -7.5 1.58 -2.1 -2.6 1.6 -1.5
TIMP3 1.31 1.83 34.4 3.75 -1.3 2.45 2.58 11.5 -1.1 3.17 9.09 5.79 2.29 4.18 2.92 2.43 -1.2 2.93 1.59 4.51 -1.2 -1.1 -1.1 -1.6 1.24 -1 1.11 -1.6
Tubb5 1.13 -1.2 2.99 1.41 2.2 1.11 2.37 2.5 1.6 2.21 1.55 -1.7 -1.3 -2.4 1.34 -1.9 1.23 -1.5
UBC -1.3 -1 11.4 2.07 -1.3 1.6 3.59 2.75 -1.9 1.07 3.95 2.28 1.09 1.43 1.2 -1.9 -1.6 1.39 -1.4 1.53 -1.7 -1.2 -1.4 -1.5 -1.3 -1 1.01 -1.1
vim 1.26 -1.6 2.34 -1.1 -1.1 2.84 2.61 1.78 -1.5 3.06 5.17 3.62 1.19 1 1.14 1.03 -1.1 1.8 1.17 1.26 1.2 -1.1 1.45 -1.5 1.53 1.1 1.24 -1.1
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ID9637 Doxorubicin Sulfasalzine Rotenone Aniline Dihydrocourmarin 2,4diaminotoluene  
In case of doxorubicin treatment at 20 mg/kg dose, most of the induced genes could occur in the 
heart and the kidney which is in good concordance with the known toxicity of this chemotherapeutic 
agent [34]. To test concentration dependent changes, doxorubicin was applied at lower concentration 
as well (5 mg/kg). As expected at lower doses smaller number of genes were affected (3 vs. 6 in the 
brain, 11 vs. 28 in the kidney, 2 vs. 18 in the heart, and 8 out of 11 in the liver). Moreover, at lower 
doses almost all genes that showed more than 2-fold gene expression alteration were similar to those 
that exhibited significant changes at higher doses (data not shown). 
High toxicity of i.p. administered sulfasalzine, a widely used anti-inflammatory agent, could be 
registered based on its dramatic effects on gene expression in all organs, except in the brain, which 
might be due to its lower toxicity at this concentration or lower penetration ability through the blood Int. J. Mol. Sci. 2011, 12  6124 
 
 
brain barrier. Rotenone, a pesticide and mitochondrial complex I inhibitor, caused general toxicity 
when administered  into animals [35]. Interestingly,  although rotenone induces oxidative stress,  we 
could register brain, liver and kidney toxicity and no, or very slight cardiotoxicity based on the number 
of genes altered in our study (Figure 2). Similarly, aniline and dihydrocoumarin induced marker gene 
expression  changes  in  the  liver  and  kidney,  however  they  resulted  in  completely  different  gene 
expression  profiles:  aniline  induced  16  gene  markers,  while  dihydrocoumarin  down-regulated  
10 genes, out of which 6 were in common with those affected by aniline. 2,4-diaminotoluene, a known 
hepatotoxic agent [36], resulted in a very specific hepatotoxic gene expression signature and induced 
hardly any changes in gene expression in the other three organs. 
2.1.4. Profiling of Drugs and Prodrugs 
For our in-house drug discovery program, we used our toxicogenomic screen for early prediction of 
side  effects.  Mice  were  treated  with  30  mg/kg  Ac-915,  a  novel  lipid-droplet  binding  thalidomide 
analog  [37]  and  with  20  mg/kg  ID9637,  a  fatty  acid  derivative,  as  a  novel  anticancer  drug  
candidate [38]. By using the QRT-PCR profiling of different organs of the treated animals, Ac-915 
resulted in 3 induced genes in brain samples, 1 repressed gene in the heart, 9 induced genes in the liver 
and  10  induced  genes  in  the  heart  (data  not  shown).  ID9637  caused  massive  gene  expression 
alterations in all of the tested organs (brain: 8 genes, heart: 24 genes,  liver: 12 genes and kidney:  
20 genes) (Figure 2). These results suggested that at these concentrations these compounds are highly 
toxic, which was well correlated by classical toxicology end-point results. 
In our toxicogenomic test we also studied Trisequens N, which is a hormone replacement therapy 
preparation. It consists of estradiol hemihydrate alone and in combination with norethisterone acetate. 
Estradiol  hemihydrate  is  a  naturally  occurring  form  of  estrogen  and  norethisterone  acetate  is  a 
synthetic form of progesterone [39]. By applying these drugs to mice we detected minor changes in 
gene expression. In the brain only one gene was repressed (spp1) by the estradiol treatment and one 
was induced (timp2) by oestrogen and norethisterone treatment. Similarly in the heart the expression of 
only one gene was elevated  in each case (skp2  for estradiol alone and tubb5  for the combination 
treatment), in the liver one gene was repressed by both treatments (ldh3b) and one additional induction 
occurred in response to estradiol (Slc25a17). In the kidney the expression of gclc was up-regulated in 
animals receiving the drug combination, while in both treatment groups two additional genes were 
repressed (fabp4 and pparg). These changes are minor and could represent individual deviations and 
most probably they do not account for toxic side effects.  
We  intended  to  apply  our  toxicogenomic  platform  to  see  whether  the  toxic  activities  of  a  
prodrug  (irinotecan)  and  its  active  metabolite  (7-ethyl-10-hydroxycamptothecin,  SN-38)  could  be 
differentiated.  Heart,  brain,  kidney  and  liver  were  dissected  from  4-4  treated  animals  and  gene 
expression  profiling  was  done  with  nanocapillary  QRT-PCR  over  a  discovery  gene  set  of  
56 toxicology biomarkers. A single gene was induced by irinotecan (hspcb by 4.72-fold) out of 56 
genes  examined  in  the  brain  samples,  while  SN-38  treatment  resulted  in  one  repressed  (c-fos  by  
2.39-fold) and four induced genes (skp2: 2.5-fold; vim: 2.28-fold; nqo1:3.14-fold; sod1: 4.76-fold). 
In the kidney 5 and 7 genes were affected by irinotecan and SN-38, respectively. All of the 5 genes 
which were up-regulated in response to irinotecan were found to be induced as well, in the SN-38 Int. J. Mol. Sci. 2011, 12  6125 
 
 
treated samples. These genes were the following: gclc: 3.39-fold and 5.70-fold; pepck: 2.91-fold and 
3.43-fold;  odc1:  2.77-fold  and  4.38-fold;  fabp4:  2.75-fold  and  5.28-fold;  pparg:  3.07-fold  and  
3.03-fold, in the irinotecan and SN-38 treated kidney tissues, respectively. Two genes were induced 
only in the SN-38 treated group: hspa1a by 3.14-fold and fga by 3.01-fold. 
In the liver more striking difference could be observed between the two groups: irinotecan induced 
one gene (kap by 3.6-fold) and down-regulated one gene (clu by 2.2-fold), while SN-38 treatment 
elevated the mRNA level of 5 genes (serpine1 by 5.58-fold, skp2 by 2.69-fold, pgam2 by 2.51-fold, 
gadd153 by 3.78-fold and trp2 by 16-fold). 
In the heart 2 genes were repressed (odc1 by 2.04-fold and ccng1 by 2.91) and one was induced 
(prdx1  by  2.33-fold)  in  response to  irinotecan,  while  altogether the  expression  of  8  marker  genes  
were affected by SN-38 (induced: odc1 by 2.56-fold, prdx1 by 2.58-fold, ftl1 by 8.28-fold, tubb5 by 
2.56-fold, gpx4 by 2.97-fold, ccng1 by 2.69; repressed: kap by 2.89-fold and hint1 by 5.39-fold). 
2.1.5. Comparison of Data from Toxicogenomic and Histological Analysis 
To test whether toxicology-related gene expression changes can be correlated with pathological 
observations  on  histological  samples,  we  selected  two  treated  groups  from  those  samples  where 
significant number of altered genes could be registered.  
Histological  sectioning  and  analysis  from  groups  treated  with  ID9637  and  sulfasalazin  were 
performed. In the brain, heart and kidney we could not observe any histological changes in the treated 
groups. Any signs of toxic side effects could be observed in other organs (spleen, lungs and liver) from 
the  sulfasalazin  group  (see  pictures  in  Supplementary  Figure  1).  In  the  liver  the  ID9637  treated 
animals' medium portal-periportal inflammation and gathered fibrin-pus in the fibrotic liver capsule 
could be observed (see pictures in Supplementary Figure 2). 
2.2. Discussion 
During the drug developmental process, undesired toxicity accounts for about one third of compound 
failures  [40].  However,  hepatotoxicity  is  a  common  reason  for  withdrawal  of  compounds  from  the 
market  [41],  drug-induced  toxicity  affecting  other  organs,  including  kidney,  heart  and  the  central 
nervous system, is a common finding in the preclinical phase of drug development [39,42]. Therefore, 
it  is evident that new technologies are needed as an alternative to classical toxicological tests for 
prediction of side effects specific to different organs. Toxicogenomics is an emerging technology that 
uses novel genomic methods to investigate the adverse effects of small molecules at the transcriptome 
level  including  DNA  microarrays,  new  generation  sequencing  and  QRT-PCR  methods  [1–3,5,20]. 
Among  the  applied  technologies  traditional  QRT-PCR  provides  high-throughput  and  accurate 
differential expression profiling of usually 10–20 selected genes with high sensitivity, reproducibility, 
and  large  dynamic  range.  However,  one  of  the  drawbacks  to  apply  traditional  QRT-PCR  in 
toxicogenomics is the relatively low throughput and the small number of genes that can be analyzed on 
multiple samples simultaneously. Because of the relatively high number of samples that are required to 
be  analyzed  and  because  of  the  better  predictive  value  of  larger  gene  sets  (50–100  genes)  for  
organ-specific toxicity, a high-throughput QRT-PCR approach is needed. Previously we confirmed the 
analytical performance of a novel, nanocapillary-based QRT-PCR, the OpenArray
TM system (Applied Int. J. Mol. Sci. 2011, 12  6126 
 
 
Biosystems, previously Biotrove Inc.) for toxicogenomic screening of 668 compounds for their gene 
expression profiles in HepG2 cells [2]. This high-throughput QRT-PCR has a capacity of running about 
18,000 reactions per day and it is optimal for analyzing numerous samples over 56–112 gene markers. 
It is clear that there are a number of limitations using in vitro approaches such as the functional 
differences observed in primary cells relative to the intact organs, the absence of interactions with 
biological  borders  and  matrices  (i.e.,  for  ADME  effects)  under  in  vitro  conditions,  which  are 
representative of an in vivo situation. Therefore, our objective was to develop an in vivo toxicogenomic 
screening to analyze multiple organs after systemic administration of the tested compound. Because of 
the relatively high number of samples needed for our test (multiple organs from numerous biological 
replicates) the OpenArray
TM platform was adopted to determine relative changes in expression of 56 
toxicology-related genes. 
Based on our previous, and on literature, data from DNA-microarray experiments, 56 gene markers 
were selected coding for proteins having roles in acute phase response, inflammation, oxidative stress, 
metabolic  processes,  heat-shock  response,  cell  cycle/apoptosis  regulation  and  detoxification.  The 
ideology  of  gene  selection  was  that transcriptional  regulation  of  the  genes  should  be  observed  in 
response  to  drug  treatment  that  had  been  suggested  as  markers  for  early  stages  of  toxic  effects, 
therefore they could be used as predictive markers. Some of the genes are induced upon xenobiotic  
or toxic compounds in a specific organ, while others are general indicators of toxicity of multiple 
organs. Previous studies showed that gene expression profiling of samples having isolated at multiple 
time-points resulted in very similar alterations to control samples regardless of treatment duration [33]. 
Based on this observation we applied different tested compounds for 16 h and brains, hearts, kidneys 
and livers were isolated afterwards. Mouse was used as model organism for our toxicogenomic study 
because  relatively  high  number of  animals  is  needed.  For  QRT-PCR  we  used  Taqman  chemistry, 
instead of SybrGreen protocol. Taqman probes were designed for mouse genes; however the same set 
of  genes  could  be  designed  for  other  organisms  as  well.  Because  of  the  open  design  of  the 
OpenArray
TM plates our discovery gene set can be further optimized having novel genes inserted or 
replacing genes responding only in very specific cases. The number of selected marker genes can be 
increased and specific genes can be inserted, especially if the mechanism of action is known for a 
compound and other pathways are affected.  
To  test  our  toxicogenomic  screening  platform  relative  gene  expression  changes  after  systemic 
administration  of  known  toxic  reference  compounds  (doxorubicin,  sulfasalazin,  rotenone,  aniline, 
dihydrocoumarin and 2,4-diaminotoluene) were determined. The number of modulated genes differed 
between the various treatments. The more genes there were affected by a compound in a certain organ, 
the more toxic effects could be verified. 
In case of doxorubicin treatment most of the induced genes could occur in the heart and the kidney 
which  is  in  good  concordance  with  the  known  toxicity  of  this  chemotherapeutic  agent.  The  most 
important cardiotoxic mechanisms proposed for doxorubicin include oxidative stress with its resultant 
damage to myocardial  elements, changes  in calcium  homeostasis and decreased ability to produce  
ATP [34]. In our study out of 10 genes that are involved in the oxidative stress response six were 
induced in the heart and five in the kidney (Figure 2). When doxorubicin was applied at two different 
concentrations dose-depentend gene expression alteration could be detected. Int. J. Mol. Sci. 2011, 12  6127 
 
 
Sulfasalazine is a drug commonly used in the treatment of inflammatory bowel diseases such as 
ulcerative colitis and Crohn’s disease and rheumatoid arthritis. Frequent incidence of side effects limits 
therapy with sulfasalazine, which is due to its effects on oxidative stress [43]. Sulfasalazine induced 
dramatic  changes  in  the  expression  of  marker  genes  in  the  liver,  in  the  kidney  and  in  the  heart 
suggesting severe toxicity when systemically applied at high doses. 
Rotenone,  a  pesticide  and  mitochondrial  complex  I  inhibitor,  triggers  general  toxicity  when 
administered to animals [35]. Interestingly, brain, liver and kidney toxicity could be registered and no 
or very slight cardiotoxicity based on the number of genes altered in the study (Figure 2). In case of 
aniline  and  dihydrocoumarin  we  found  substantial  gene  expression  modification  in  the  liver  and 
kidney, however they generated completely different gene expression profiles: aniline induced 16 gene 
markers, while dihydrocoumarin down-regulated 10 genes, out of which 6 were in common with those 
affected by aniline. Genes specifically altered by treatment of 2,4-diaminotoluene, which induce DNA 
damage, DNA repair and micronucleus formation in hepatoma cells [36], could be detected in the liver 
and not in any other organs.  
From these results we could conclude that based on early gene expression changes the present 
genomic approach is able to predict organ-specific transcriptional response. 
To demonstrate the utility of the strategy different drugs and drug candidates were profiled. In  
in-house anticancer drug discovery programs at Avidin we were able to demonstrate the high toxicity 
of  a  fatty  acid  derivative  cytotoxic  agent,  ID9637  and  cardio-  and  hepatotoxicity  of  a  novel  
lipid-droplet binding thalidomide analog [37]. 
However, gene expression changes may represent organ adaptation to chemical exposure without 
acute toxicity. The advantage of toxicogenomic screen over classical methods is to identify genetic 
elements that could be correlated and even to predict toxic insult when there is still no pathological 
readout. If a compound induces several genes that are part of the organ adaptation, one could expect 
organ toxicity or induced activity, which could end in organ failure and organ toxicity upon chronic 
administration of the drug. Histological analysis was performed from those samples where significant 
number of altered genes could be registered (in case of ID9637 and sulfasalazin). Although in the 
sulfasalazin treated organs, a high number of toxicology-related genes were induced, no pathological 
alteration could be observed in the brain, heart, kidney, spleen, lungs and liver. In the ID9637 treated 
animals, no signs of toxic effects could be observed in the histological sections of the organs, except 
the liver, where acute toxic side effects could be registered (medium portal-periportal inflammation 
and gathered fibrin-pus in the fibrotic liver capsule). From these results we could conclude that early 
gene expression changes cannot be accurately compared with pathological alterations, mainly because 
of the different time scale of the methods. 
In the present toxicogenomic test Trisequens N was also studied, which is a hormone replacement 
therapy preparation. It consists of estradiol hemihydrate alone and in combination of norethisterone 
acetate. These ingredients are forms of the main female sex hormones, estrogen and progesterone [39]. 
Estradiol  hemihydrate  is  a  naturally  occurring  form  of  estrogen  and  norethisterone  acetate  is  a 
synthetic form of progesterone. By applying these drugs to mice we were interested in whether a single 
injection results in any changes in the expression of our marker genes. No significant changes between 
the treated and the control groups were found. Although very small changes in the model of hormone 
replacement therapy were registered, interestingly, in the kidney down-regulation of both fabp4 and its Int. J. Mol. Sci. 2011, 12  6128 
 
 
transcription  regulator,  pparg  were  detected.  FABP4  is  a  lipid  binding  protein  playing  a  role  in 
intracellular  lipid transport and metabolism, as well as  in signal transduction and  its expression is 
regulated by PPAR-dependent transcriptional mechanism [44]. Both gene products are associated with 
metabolic syndrome, type 2 diabetes mellitus, cancer and atherosclerosis [44–46]. Although in the 
acute  experiment  any  significant  changes  could  be  found  in  the  expression  profiles  of  the  treated 
animals,  further  studies  on  the  expression  alteration  of  fabp4, pparg or other  gene  markers  could 
possibly highlight the effects of chronic hormone replacement therapy applied at different doses and 
could define the risk population. 
Irinotecan, a widely used chemotherapeutic agent is activated by hydrolysis to SN-38, an inhibitor 
of topoisomerase I. The inhibition of this enzyme by the active metabolite SN-38 leads to inhibition  
of both DNA replication and transcription and finally apoptosis of cancer cells. Previously Blandizzi 
and  his  co-workers  described  that  the  antitumor  drug  irinotecan  possesses  adverse  cardiovascular 
effects [47], while the same drug was demonstrated to have negative effects on renal functions [48]. 
The present toxicogenomic platform was applied in order to demonstrate whether the toxic activities of 
irinotecan and its active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38) could be differentiated. 
As irinotecan is a prodrug, it was hypothesized that it has less influence on gene expression of toxic 
markers than SN-38, when applied at the same concentrations. 
Gene expression screening results indicate that SN-38 exerts negative effects on both heart and 
kidney, as determined by altered toxic gene marker expression. Similar effects could be seen in case of 
irinotecan; however a smaller number of genes were affected. This observation is in good concordance 
with the different tolerability of the prodrug and the drug. Our results demonstrate that the presented 
toxicogenomic platform is not only able to detect organ-specific transcriptional response of different 
harmful chemicals, but also able to distinguish the toxic effects of a prodrug and its active metabolite. 
One of the limitations of our gene selection procedure is that although some of the genes might be 
useful indicators of toxicity in a specific organ, in some cases they cannot be used in other organs. 
Some genes showed lower, or even undetectable expression by nanocapillary QRT-PCR (e.g., in case 
of egf, serpinCI, saa3, kap or serpinEI) in some tissues. This organ-specific difference was  more 
pronounced in the brain, where the lesser number of genes showed altered expression, even in those 
cases where toxicity of the brain could be predicted. This problem could be overcome with precise 
selection of marker genes in the future and with developing an improved version of nanocapillary 
QRT-PCR toxicogenomic platform. 
3. Experimental Section 
3.1. Animals, Treatment, and Sample Collection 
Groups  of  4  Balb/C  female  mice,  that  were  kept  in  a  conventional  animal  house  and  received 
conventional  food  pellets  and  tap  water  ad  libitum  throughout  the  experiments,  were  injected 
intraperitoneally with 400 μL carrier solution (20% DMSO, 25% Solutol (BASF, Germany), 55% saline) 
for control, or compound dissolved in 400 μL carrier solution in the following doses: doxorubicin 
(Sigma-Aldrich, Budapest, Hungary): 5 mg/kg and 20 mg/kg; rotenone (Sigma-Aldrich): 30 mg/kg; 
aniline  (Sigma-Aldrich):  150  mg/kg;  sulfasalazin:  30  mg/kg;  dihydrocoumarin  (Sigma-Aldrich):  Int. J. Mol. Sci. 2011, 12  6129 
 
 
80  mg/kg;  2,4-diaminotoluene  (Sigma-Aldrich):  80  mg/kg;  irinotecan  (Sigma-Aldrich):  10  mg/kg;  
SN-38 (Sigma-Aldrich): 10 mg/kg; Ac-915 (Avidin, Szeged, Hungary): 30 mg/kg; ID9637 (Avidin): 
20 mg/kg; estradiol: 200 μg/kg and combination of 200 μg/kg estradiol and 100 μg/kg norethisterone 
(Novo Nordisk, Bagsværd, Denmark). After 16 h brains, hearts, kidneys and livers were isolated and 
stored  in  RNA-Later  (Ambion,  USA)  at  4  °C  overnight.  All  animal  experiments  were  performed 
respecting institutional animal welfare guidelines. 
3.2. RNA Isolation 
RNA  isolation  from  heart  tissue  was  performed  as  published  [49].  Briefly,  our  protocol  is  an 
improved  version  of  the  High  Pure  miRNA  Isolation  Kit  (Roche,  Cat.  No.  05080576001)  with 
inserting  several  additional  steps  into  the  standard  protocol.  Mouse  hearts  were  frozen  and 
homogenized at the temperature of liquid nitrogen. To 50 mg tissue powder 190 μL proteinase  K 
solution was added (prepared as follows: 120 μL Paraffin Tissue Lysis Buffer (Roche, Germany),  
20 μL 10% SDS and 50 μL Proteinase K (Roche). Samples were incubated at 55 °C for 30 min. After 
incubation 325 μL Binding Buffer (Roche) and 320 μL Binding Enhancer (Roche) was added and 
loaded onto the filter columns (Roche). Next the filters were washed in two steps with 500 and 300 μL 
of Washing Buffer (Roche) then the RNA was eluted by adding 40 μL Elution Buffer (Roche). The 
quality and quantity was assessed spectrophotometrically (Nanodrop, USA) and considered acceptable 
if the absorption ratio of 260/280 was >1.8. 
Brain tissue was homogenized in Trizol reagent (Sigma), liver and kidney was homogenized in 
RA1 buffer (Machery-Nagel, USA). Total RNA was purified from drug treated and control organs 
with AccuPrep
TM RNA purification kit (Bioneer, Daeleon,  Korea) according to the manufacturers’ 
protocol,  except  that  DNase  I  treatment  was  incorporated.  Homogenized  tissues  were  centrifuged 
through NucleoSpin  Filters (Machery-Nagel 740606,  13,000 rpm,  3  min  in Eppendorf centrifuge). 
Pellet  was  suspended  in  RA-1  lysis  buffer  (Machery-Nagel,  740961.500)  supplemented  with  
β-mercaptoethanol. Equal volume of 70% ethanol was also added, samples were vortexed, and were 
loaded  onto  extraction  columns  (Bioneer  Viral  RNA  Extraction  Kit,  KA-1111).  Columns  were 
centrifuged with 13,000 rpm, 1 min in Eppendorf centrifuge, washed with 80% ethanol, than treated 
with DNase for 15 min at RT. Reaction was stopped with RA1:EtOH (1:1), centrifuged, then washed 
twice with Wash Buffer 2 (Bioneer, KB1052). RNA was eluted with 50 μL RNase free water at 55 °C, 
and the concentration was determined by Nanodrop. After addition of RNase inhibitor, samples were 
stored at −80 °C. 
For QRT-PCR total RNA (750 ng) was converted into cDNA with the High-Capacity cDNA RT 
Kit (Applied Biosystems, Foster City, CA, USA) and without purification the mixture was diluted with 
RNase-free water and applied to QRT-PCR analysis. 
3.3. Profiling of RNAs with High-Throughput, Nanocapillary QRT-PCR 
Amplification of the samples was followed in real time with an OpenArray NT Cycler (BioTrove 
Inc., Woburn, MA; Applied Biosystems, Foster City, CA, USA). For our discovery gene set individual 
Taqman assays were specified (Table 1). An aliquot of each Taqman assay was sent to BioTrove 
(Woburn, MA, USA) for loading in their OpenArray plates. Taqman assays are purchased individually Int. J. Mol. Sci. 2011, 12  6130 
 
 
and  loaded  by  BioTrove  (now  at  Applied  Biosystems,  Life  Technologies)  in  a  customer-specified 
layout.  Recently,  the  list  of  the  genes  is  available  to  prepare  the  custom-designed  plates  by  the 
company. A third fluorescent dye (ROX), present in the Taqman assay mixture, was imaged to provide 
quality assessment of manufacturing and loading of the arrays. 
The reverse transcribed samples (or water for no template controls) were added to a 384-well plate 
containing  GenAmp  Fast  PCR  Master  Mix  (Applied  BioSystems,  Foster  City,  CA,  USA)  and 
OpenArray  DLP  5×  Remix  Solution  (BioTrove  Inc.,  Woburn,  MA,  USA)  for  OpenArray 
amplification. The OpenArray autoloader transfers the cDNA/master mix from the plate to the array 
through-holes by capillary action. Each subarray was loaded with 5.0 μL of master mix containing 
1.2 μL of reverse transcribed cDNA. The array is manually transferred to the OpenArray slide case and 
sealed. The plates were cycled in the OpenArray NT cycler (up to three arrays simultaneously) under 
the following conditions: 50 °C for 15 s, 91 °C for 10 min, followed by 50 cycles of 54 °C for 170 s 
and 92 °C for 45 s. 
The Biotrove OpenArray NT Cycler System software (version 1.0.2) uses a proprietary calling 
algorithm that estimates the quality of each individual threshold cycle (CT) value by calculating a CT 
confidence value for the amplification reaction. In our assay, CT values with CT confidence values 
below 300 (average CT confidence of the non-target amplification reactions plus 3 standard deviations) 
were considered background signals. Higher CT confidence levels were considered positive and were 
analyzed  further.  Normalization  was  done  by  using  the  average  CT  values  of  three  house-keeping 
genes (ppia, pgk1 and rplp0) and gene expression changes were calculated from the average of four 
replica experiments. Average values were accepted when the STD was below 0.5-fold of the average.  
4. Conclusions 
Here we report the application of a high-throughput, nanocapillary QRT-PCR-based toxicogenomic 
method to an in vivo organ-specific assay for cost-effective and robust testing of compounds. Although 
only a small set of known toxic chemicals was tested, our findings were in good correlation with 
previous  toxicology  studies.  Besides  verification  data,  we  applied  our  strategy  to  drugs,  drug 
candidates  and  prodrugs,  which  provided  novel  marker  gene  expression  changes.  These  unique 
fingerprints underline the importance of expression profiling of a focused set of genes on different 
organs and warrant further development and full validation of such an alternative testing strategy for 
preclinical and environmental toxicology. 
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